The availability of a range of specific anti‐inflammatory interventions has revolutionized treatment of patients with RA and other autoimmune conditions; TNF‐α blockers and IL‐6 receptor blockers are now common and efficacious (if expensive) second or third line treatment options after use of conventional disease modifying anti‐rheumatic drugs. The gene discussed is TNF; the disease is rheumatoid arthritis.